{"id":453527,"date":"2021-03-09T08:03:10","date_gmt":"2021-03-09T13:03:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453527"},"modified":"2021-03-09T08:03:10","modified_gmt":"2021-03-09T13:03:10","slug":"iqvia-virtual-trial-solutions-used-in-more-than-60-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/","title":{"rendered":"IQVIA Virtual Trial Solutions Used in More than 60 Trials"},"content":{"rendered":"

<\/p>\n

IQVIA Virtual Trial Solutions Used in More than 60 Trials<\/b><\/p>\n

To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas<\/i><\/p>\n

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE<\/a>)–IQVIA<\/a>\u2122 (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical research and the proliferation of technology-enabled options that enable decentralized trials.\n<\/p>\n

\n\u201cPatient-centricity is at the core of decentralized and hybrid trial design. We used to bring the patient to the trial, but now we bring the trial to the patient,\u201d said Costa Panagos, president, R&D Operations, IQVIA. \u201cThe idea is to design trials that fit into patients\u2019 lives in a way that is seamless with their day-to-day activities and to capture important trial information, while reducing the burden on patients and investigators alike. It also means we adapt the way we support investigative sites globally with our study concierge service and other white glove solutions.\u201d\n<\/p>\n

\nIQVIA\u2019s virtual model offers the adaptability necessary to meet a sponsor\u2019s operational requirements. The solution is supported by a range of IQVIA capabilities including direct-to-patient engagement, telehealth technologies, virtual site management, and home health nursing.\n<\/p>\n

\nIQVIA is currently managing a mix of fully virtual trials and hybrid trials for several clients including five of the top-10 pharma companies globally, enrolling more than 150,000 subjects in a range of therapy areas since inception. Those areas of investigational clinical research include: COVID-19 vaccines and treatments, immunology, central nervous system disorders, cardiovascular, oncology, dermatology, and various infectious diseases.\n<\/p>\n

ABOUT IQVIA<\/b><\/p>\n

\nIQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence\u2122 delivers powerful insights with speed and agility \u2014 enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.\n<\/p>\n

\nIQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA\u2019s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviours and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com<\/a>.\n<\/p>\n

IQVIAFIN<\/b><\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210309005020\/en\/<\/a><\/span><\/p>\n

\nTor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com<\/a>)
\n
+1.484.567.6732\n<\/p>\n

\nAndrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com<\/a>)
\n
+1.973.257.7144\n<\/p>\n

KEYWORDS:<\/b> United States North America North Carolina Connecticut<\/p>\n

INDUSTRY KEYWORDS:<\/b> Data Management Health Technology Software General Health Clinical Trials Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

IQVIA Virtual Trial Solutions Used in More than 60 Trials To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA\u2122 (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical research and the proliferation of technology-enabled options that enable decentralized trials. \u201cPatient-centricity is at the core of decentralized and hybrid trial design. We used to bring the patient to the … <\/p>\n

Continue reading “IQVIA Virtual Trial Solutions Used in More than 60 Trials”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453527","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nIQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IQVIA Virtual Trial Solutions Used in More than 60 Trials To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA\u2122 (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical research and the proliferation of technology-enabled options that enable decentralized trials. \u201cPatient-centricity is at the core of decentralized and hybrid trial design. We used to bring the patient to the … Continue reading "IQVIA Virtual Trial Solutions Used in More than 60 Trials"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T13:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IQVIA Virtual Trial Solutions Used in More than 60 Trials\",\"datePublished\":\"2021-03-09T13:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/\"},\"wordCount\":541,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/\",\"name\":\"IQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-03-09T13:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IQVIA Virtual Trial Solutions Used in More than 60 Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/","og_locale":"en_US","og_type":"article","og_title":"IQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk","og_description":"IQVIA Virtual Trial Solutions Used in More than 60 Trials To date, IQVIA has enrolled more than 150,000 subjects across 10 therapy areas DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–IQVIA\u2122 (NYSE:IQV) announced today that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials. Many of these trials, launched in 2020 as virtual and patient-centric solutions, are providing business continuity measures to sponsors during the global pandemic. This milestone reflects the growing need for flexibility in clinical research and the proliferation of technology-enabled options that enable decentralized trials. \u201cPatient-centricity is at the core of decentralized and hybrid trial design. We used to bring the patient to the … Continue reading \"IQVIA Virtual Trial Solutions Used in More than 60 Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T13:03:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IQVIA Virtual Trial Solutions Used in More than 60 Trials","datePublished":"2021-03-09T13:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/"},"wordCount":541,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/","name":"IQVIA Virtual Trial Solutions Used in More than 60 Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-03-09T13:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210309005020r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iqvia-virtual-trial-solutions-used-in-more-than-60-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IQVIA Virtual Trial Solutions Used in More than 60 Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453527"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}